Notification letter to non-registered holder and request form
Filed with HKEX · Stock code 1093 · · 2 pages · English and Chinese
The English and Chinese versions of the Current Corporate Communications are available on the Company’s website at www.cspc.com.hk and the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk. If you would like to receive the Current Corporate Communications and all future corporate communications# in printed form, please complete the Request Form on the reverse side of this lette
CSPC Pharmaceutical Group Limited on 6ix
Earlier from CSPC Pharmaceutical
- Letter to new registered shareholders and reply form
- 2026 Interim report
- Voluntary announcement - phase II clinical trial of SYH2069 injection for the treatment of type 2 diabetes mellitus in adult patients officially initiated at the first centre in China
- Voluntary announcement - SYS6010 granted Breakthrough Therapy Designation by NMPA in China for the treatment of patients with actionable genomic alteration-negative non-squamous non-small cell lung cancer
- Voluntary announcement - phase i/ii clinical trial data of SYS6010 in combination with enlonstobart for the treatment of systemic treatment-naive, actionable genomic alteration-negative advanced nsclc orally presented at the 2026 world conference on lung cancer (wclc)
Later from CSPC Pharmaceutical
- Voluntary announcement - phase III clinical trial of docetaxel for injection (albumin-bound) (HB1801) for the treatment of advanced breast cancer officially initiated in china
- Voluntary announcement - phase III clinical trial of becotatug (JMT101) in combination with osimertinib for the first-line treatment of locally advanced or metastatic NSCLC harbouring EGFR exon 20 insertion mutations achieves positive topline results
- Voluntary announcement - SYS6077 injection obtains clinical trial approval in China
- Voluntary announcement - recombinant herpes zoster vaccine (SYS6052) obtains clinical trial approval in the U.S.
- Voluntary announcement - Phase Ib clinical trial of JMT206 injection for weight management in adult patients with overweight or obesity officially initiated at the first study centre in China
Follow CSPC Pharmaceutical into a list and get an email when it puts out news.
Follow CSPC Pharmaceutical